{
    "Trade/Device Name(s)": [
        "INNOVANCE Antithrombin"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics Products GmbH",
    "510(k) Number": "K242952",
    "Predicate Device Reference 510(k) Number(s)": [
        "K933125"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "JBQ"
    ],
    "Summary Letter Date": "March 28, 2025",
    "Summary Letter Received Date": "September 25, 2024",
    "Submission Date": "September 20, 2024",
    "Regulation Number(s)": [
        "21CFR864.7060"
    ],
    "Regulation Name(s)": [
        "Antithrombin III assay"
    ],
    "Analyte Class(es)": [
        "coagulation"
    ],
    "Analyte(s)": [
        "Antithrombin"
    ],
    "Specimen Type(s)": [
        "Human citrated plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Siemens BCS XP System",
        "Sysmex Automated Coagulation Analyzer CA-1500",
        "Sysmex Automated Coagulation Analyzer CA-500",
        "Siemens Healthineers Automated Blood Coagulation Analyzer CA-620",
        "Sysmex Automated Blood Coagulation Analyzer CA-620",
        "Siemens Healthineers Automated Blood Coagulation Analyzer CA-660",
        "Sysmex Automated Blood Coagulation Analyzer CA-660",
        "Siemens Healthineers Automated Blood Coagulation Analyzer CS-2500",
        "Sysmex Automated Blood Coagulation Analyzer CS-2500",
        "Siemens Healthineers Automated Blood Coagulation Analyzer CS-5100",
        "Sysmex Automated Blood Coagulation Analyzer CS-5100"
    ],
    "Method(s)/Technology(ies)": [
        "Chromogenic assay"
    ],
    "Methodologies": [
        "Quantitative measurement"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Siemens INNOVANCE Antithrombin chromogenic assay for quantitation of antithrombin activity in plasma to aid in diagnosis and monitoring in hemophilia patients",
    "Indications for Use Summary": "Chromogenic assay for automated quantitation of functionally active antithrombin in human citrated plasma, used as an aid in diagnosis of antithrombin deficiency and monitoring antithrombin activity to support QFITLIA (fitusiran) dosing in adults and pediatric patients (12+ years) with hemophilia A or B with/without factor VIII or IX inhibitors",
    "fda_folder": "Hematology"
}